Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to expand the provision of capital investment for the primary care estate.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is committed to delivering a National Health Service that is fit for the future, by fixing the front door to the NHS and shifting the focus of the NHS out of hospitals and into the community. At the Autumn Budget 2024, we established a dedicated capital fund of £102 million to deliver approximately 200 upgrades to general practice surgeries across England, supporting improved use of existing buildings and space, boosting productivity, and enabling delivery of more appointments. This funding represents a first step in delivering the additional capital the primary care sector needs.
The Government recognises the importance of strategic, value for money investments in capital projects, such as new facilities, significant upgrades, or other targeted capital investments, and the Department is currently reviewing capital requirements in line with the Government’s missions and as part of our preparations for Phase 2 of the Spending Review.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase access to (a) diabetes technologies, (b) insulin pumps and (c) glucose sensors for (i) all diabetes patients and (ii) diabetes patients from deprived backgrounds.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In December 2023, the National Institute for Health and Care Excellence (NICE) published the technology appraisal guidance, Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes, which recommended hybrid closed loop as an option for managing blood glucose levels in type 1 diabetes in children and young people, and specific groups of adults. Hybrid closed loop combines a continuous glucose monitor, an insulin pump, and a computer program to automatically adjust the insulin delivery for people with type 1 diabetes. NHS England also published a five-year Hybrid Closed Loop Implementation Strategy. The rollout of the strategy commenced in April 2024. Further information on the NICE’s technology appraisal guidance is available at the following link:
https://www.nice.org.uk/guidance/TA943
Reducing inequity in access to continuous glucose monitors and insulin pumps across the most deprived quintiles and across different ethnic groups is a key objective in NHS England’s Core20PLUS5 health inequalities strategy. DigiBete, a nationally commissioned digital self-management resource for children and young people aged zero to 25 years old, includes information and videos on the latest technology available, with information provided in ten of the most commonly spoken languages. Further information on DigiBete is available at the following link:
https://www.digibete.org/type-1-technology-resources/
Data from the National Diabetes Audit suggests that the number of people with type 2 diabetes using continuous glucose monitoring is increasing. In 2022/23, 37,000 people were using a continuous glucose monitor, rising to 95,000 people in 2023/24, and 155,000 people in 2024/25. Metrics that are useful for health systems to monitor access to glucose monitoring will be published later this year.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce the risk of young adults developing Type 2 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department continues to take steps to reduce the risk of type 2 diabetes in young adults through the Healthier You NHS Diabetes Prevention Programme (NHS DPP). The programme supports individuals aged between 18 and 80 years old to reduce their risk of developing type 2 diabetes through lifestyle changes, and has proven highly effective. More than 840,000 people have been supported through the NHS DPP, reducing their risk by 37% compared to those who did not attend.
The NHS DPP continues to work in close partnership with Diabetes UK, who raises awareness amongst the public of the symptoms of type 2 diabetes in children, young people, and adults through their website, social media channels, and local campaigns.
We are committed to tackling the obstacles driving obesity. We have already laid secondary legislation to restrict advertisements of less healthy food and drink to children on television and online, announced changes to the planning framework for fast food near schools, and we are taking steps to ensure the Soft Drinks Industry Levy remains effective and fit-for-purpose. We are also committed to banning the sale of high-caffeine energy drinks to under 16-year-olds.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to identify people exposed to Diethylstilbestrol.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will provide regular screening for people exposed to Diethylstilbestrol in utero.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK National Screening Committee (UK NSC), which advises the Government on screening programmes, has never been asked to consider the evidence for screening people exposed to diethylstilbestrol in utero.
Any individual or organisation can submit a topic to the UK NSC to consider a new screening programme via the UK NSC’s annual call, with further information available at the following link:
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of exposure to Diethylstilbestrol on children of women who took that drug while pregnant.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Medicine and Healthcare products Regulatory Agency continuously assesses the benefit and risk balance of all medicines, at the time of initial licensing and throughout their use in clinical practice, carefully evaluating any emerging evidence on their benefits and risks.
In 1971, it was recognised that diethylstilbestrol (DES) could cause a distinct type of cancer in the daughters of women who took DES in early pregnancy. Shortly afterwards its use was contraindicated in pregnancy, pre-menopausal women, children, and young adults, and the Committee on Safety of Medicines wrote to all doctors in May 1973 to advise against the use of DES in pregnant and pre-menopausal women.
A small increased risk of breast cancer in women who received DES whilst pregnant was first identified in the 1980s and confirmed in further studies in the 1990s, when a longer follow up of women who had taken DES was available. No increased risk of other cancers has been established, including endometrial cancer or ovarian cancer.
Since 1992, the National Cancer Institute at the US National Institutes of Health has been conducting the DES Follow-up Study of more than 21,000 mothers, daughters, and sons exposed in the womb during the mother’s pregnancy, to better understand the long-term health effects of exposure to DES. The findings of this follow up have been published in scientific literature.
Daughters of individuals exposed to DES are at increased risk of clear cell cancer of the cervix and vagina. The current advice from the UK Health Security Agency, formerly Public Health England, is that routine cervical screening is appropriate for those who believed they were exposed to DES in utero. Further information on the UK Health Security Agency’s advice is available at the following link:
Participation in the National Breast Screening Programme is also recommended. Pregnant women who know that they were exposed in utero to DES should inform their obstetrician and be aware of the increased risks of ectopic pregnancy and preterm labour.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that NHS Data Security and Protection Toolkit (a) guidance and (b) training is adequate to ensure that NHS staff are compliant with the UK General Data Protection Regulation when working (i) at their place of work and (ii) remotely.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The main source of the UK General Data Protection Regulation (UK GDPR) and information governance (IG) guidance and advice for health and care is the NHS England IG portal, which is available at the following link:
https://transform.england.nhs.uk/information-governance/
The Data Security and Protection Toolkit (DSPT) includes IG elements to ensure that organisations meet UK GDPR standards. Accompanying DSPT guidance created for small and large health and social care organisations signposts to the IG portal, with further information for both small and large health and social care organisations available, respectively, at the following two links:
The IG portal guidance is produced on behalf of NHS England, the Department, and key national stakeholders. It is approved by the Information Commissioner’s Office, the United Kingdom’s regulatory authority for data protection, and the National Data Guardian, the independent advisory body for ensuring people’s confidential data is safe.
The IG portal provides guidance on a range of topics, including when working remotely, as, for example, it includes guidance on video conferencing and frequently asked questions on accessing information when working from home, with further information on both video conferencing and the frequently asked questions available, respectively, at the following two links:
To comply with the DSPT training requirements, the vast majority of health organisations use the centrally provided NHS England Data Security Awareness (DSA) course. NHS England reviews the DSA training on an annual basis to ensure that it reflects current best practice for using, sharing, and protecting information.
In addition, the Joint Cyber Unit of NHS England and the Department provides online IG training modules, including simple and engaging training for front line staff on information sharing, with further information available at the following link:
https://portal.e-lfh.org.uk/Component/Details/750310
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help support hospitals to (a) recruit and (b) retain clinical staff in Oxfordshire.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Decisions about recruitment are matters for individual National Health Service trusts. NHS trusts manage their recruitment at a local level, ensuring they have the right number of staff in place, with the right skill mix, to deliver safe and effective care.
That said, we are committed to training the staff the NHS needs, including clinical staff, and ensuring that the NHS remains an attractive place to work for our staff across the country. NHS England already has an extensive retention programme which is addressing matters that are important to staff, such as good occupational health support, options for working more flexibly, and better culture and leadership.
This summer we will publish a refreshed Long Term Workforce Plan to ensure the NHS has the right people, in the right places, with the right skills to deliver the care patients need when they need it.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many vacancies for (a) administrative staff, (b) clinical staff and (c) managers there are in the Oxford University Hospitals NHS Foundation Trust; and what the average time was for a vacancy to be open in (i) Oxfordshire and (ii) the UK in the last five years.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department does not hold information on trust level vacancies by staff groups, or information on the lengths of time that vacancies have been open at a local or national level.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of certified Auditory Verbal Therapists.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Audiology services in the National Health Service, including provision of therapies for children with hearing loss, are locally commissioned.
In summer 2025, we will publish a refreshed Long Term Workforce Plan to deliver the transformed health service we will build over the next decade and treat patients on time again.